MDS-Patienten profitieren anhaltend von der Behandlung mit r-HuEPO und G-CSF

Publisher： Karger

E-ISSN： 1660-3818|25|2-3|188-188

ISSN： 1660-3796

Source： Transfusion Medicine and Hemotherapy, Vol.25, Iss.2-3, 1998-06, pp. : 188-188

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

ASCO 2010: Stellenwert von Sunitinib und Temsirolimus bestätigt mRCC-Patienten profitieren vonLangzeittherapie mit Sunitinib

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-09 ,pp. : 483-483

Karger

Access to resources Recommend Favorite

rHuEPO Dose Inversely Correlated with the Number of Circulating CD34+ Cells in Maintenance Hemodialysis Patients

By  

Nephron Clin Pract, Vol. 108, Iss. 1, 2007-12 ,pp. : c41-c46

Karger

Access to resources Recommend Favorite

Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced Anemia

By  

Oncology Research and Treatment, Vol. 28, Iss. 4, 2005-10 ,pp. : 216-221

Karger

Access to resources Recommend Favorite

Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes

By  

Acta Haematologica, Vol. 120, Iss. 2, 2008-10 ,pp. : 104-107

Karger

Access to resources Recommend Favorite

Kommentar zur Originalarbeit «COPD und Klangtherapie: Pilotstudie zur Wirksamkeit einer Behandlung mit Körpertambura bei COPD-Patienten» von Hartwig et al:

By  

Forschende Komplementärmedizin / Research in Complementary Medicine, Vol. 23, Iss. 4, 2016-08 ,pp. : 253-253

Karger

Access to resources Recommend Favorite